Avalo Therapeutics

AVTX-002 Clin2 (fast track) COVID-19 ARDS, Clin2 (failed Jun 2023) non-eosinophilic asthma, Clin1 Crohn's; AVTX-008 RD/Clin0 immunoregulatory disorders

Avalo Therapeutics is creating treatments for patients with unmet clinical needs in immunology and rare genetic diseases. At the core of Avalo’s therapeutics is immune regulation by targeting the LIGHT-signaling network. LIGHT is a newly recognised cytokine with inflammatory actions in the lung, gut and skin, encoded by the TNFSF14 gene. The LIGHT immune regulatory network is suggested to be dysregulated and a disease-driving mechanism in autoimmune and inflammatory reactions. By reducing signaling through the LIGHT-signaling network, Avalo hopes to moderate immune dysregulation. Avalo’s pipeline includes various biologics focused on dysregulated inflammation via the LIGHT-signaling network with several in clinical stages.

Jobs: